No Prescription |
 |
 | ||
|
FENOLIP Antara |
|
| ||
No Prescription » Prescription Drugs 7 » FENOLIP Antara Fenofibrate is used for: Controlling high cholesterol and triglyceride levels in the blood. It is used in combination with a diet low in cholesterol and saturated fat.Fenofibrate is a lipid-lowering agent. It lowers elevated blood triglyceride levels by making the liver produce fewer triglycerides and increasing the elimination of triglycerides from the blood streamFenofibrate helps reduce cholesterol and triclygerides (fatty acids) in the blood. High levels of these types of fat in the blood are associated with an increased risk of atherosclerosis (clogged arteries).Fenofibrate is used to treat high cholsterol and high triglyceride levels.Fenofibrate is used along with a special diet to treat people with very high levels of triglycerides (a fatty substance in the blood). Fenofibrate also improves cholesterol levels by lowering total cholesterol--including "bad" LDL cholesterol--and raising "good" HDL cholesterol. It works by promoting the dissolution and elimination of fat particles in the blood.Fenofibrate is usually added to a treatment regimen only when other measures have failed to produce adequate results. Often diet and exercise are enough to bring blood fats under control. Likewise it's sometimes sufficient to simply treat an underlying problem such as diabetes underactive thyroid kidney disease liver dysfunction or alcoholism. And in some cases just discontinuing a medication is enough to do the job. For instance certain water pills and "beta-blocker" heart medications are capable of causing a massive increase in triglyceride levels. Estrogen replacement therapy is another potential culprit.Whatever your other treatment measures may be it's important to remember that Tricor is intended to supplement them rather than replace them outright. To get the full benefit of the medication you need to stick to the diet exercise program and other treatments your doctor prescribes. All these efforts to keep your cholesterol and triglyceride levels normal are important because together they may lower your risk of heart disease. If you're judged to be at high risk of heart disease current guidelines call for considering drug therapy when LDL levels reach 130. For people at lower risk the cut-off is 160. For those at little or no risk it's 190. Buy FENOLIP Antara and other Prescription Drugs 7 products online at Medstore. 3506
About FENOLIP Antara: Product Type: Prescription Drugs 7 FENOLIP ( Antara Lipofen Tricor Triglide Generic Fenofibrate ) FENOLIP (Antara Lipofen Tricor Triglide Generic Fenofibrate) Antara Lipofen Tricor Triglide Generic Fenofibrate 160mg 100 ( 10 x 10 ) Tabs Antara Lipofen Tricor Triglide Generic Fenofibrate FENOLIP
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
